


ASH 2022

CML Advocates Network conference report



64th ASH[®] Annual Meeting and Exposition

December 10 – 13, 2022 • New Orleans, Louisiana



Denis Costello, ED CMLAN

Jan Geissler, Chair

Eglys González, Project Manager



64th ASH Annual Meeting & Exposition

The 64th ASH Annual Meeting and Exposition took place in December 10-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Representatives from the CML AN were there participating in several activities and sessions. Our chair Jan Geissler was invited to give a presentation on **the importance of patient involvement in data-driven blood cancer research** within the HARMONY Alliance special session. Zack Pemberton-Whiteley, a member of our Steering Committee presented a poster with results of a multi-country survey on **experiences and views of leukemia patients**. Other patient advocates like Gerald Clements, Lisa Machado, Pat García-González, Denis Costello, Samantha Nier, and Eglys González, were also there.

Here we present this conference report that summarizes the key CML highlights of interest to the patient advocacy community.




Education Session: Beyond Routine Frontline Therapy of CML

Treatment of TKI resistant chronic phase CML.

Timothy Hughes, MD

- Discussion of assessments and selecting the optimal TKI and TKI doses in CP-CML patients with TKI resistance. Tolerance, mutation profile, co-morbidities, and cardiovascular risk factors should be considered in the context of their prior response.
- Description and benefits of Asciminib were mentioned, concluding it has good efficacy and safety as monotherapy particularly when the disease is still responsive.
- Case reports and ongoing clinical studies were addressed. Indicating the complexity of an optimal third-line selection. Concluding that assessment to information regarding resistance status, mutations and CVS risk are needed.



Recommended Treatment Matrix for 2G TKI Resistance

3. Primary refractory or high-grade resistance	ponatinib	asciminib
2. Partially responsive Resistance	ponatinib	asciminib
1. Failure to achieve optimal molecular target		asciminib

Cardiovascular risk assessment

Low cardiovascular risk High cardiovascular risk

American Society of Hematology

64th ASH Annual Meeting and Exposition

64th ASH Annual Meeting

Education Session: Beyond Routine Frontline Therapy of CML

Transplantation in CML in the TKI Era: Who, When, How? Nicolaus Kroeger, MD

- Discussion on integrating allogeneic SCT as a curative treatment approach for chronic and advanced phases of CML. Use of allogeneic SCT in first and second chronic phase (CP1 & CP2), and in accelerated phase (AP). Conclusion is that it is still a curative treatment option for patients resistant or intolerant to TKIs, in both AP and BC. Better outcome in first chronic phase.
- Risk factors like cytogenetic, molecular genetics, BCR/ABL mutations, and BM fibrosis should be considered.
- Ongoing improvements in 3rd generation TKIs or STAMP inhibitors may modify further indications of allogeneic SCT.


For whom consider allogeneic SCT for CML?

Disease specific risk factors:

1. Additional high risk chromosomal abnormalities (ACA): such as der 3, 7,17,19,21,-7 +8
2. High ELTS (EUTOS) score
3. Bone marrow fibrosis
4. Additional Molecular genetics (e.g ASXL-1)
5. Recurrent cytopenia

Patient specific factors:

1. Younger Age
2. Patient's wish
3. Good Performance status/ high Karnofsky index / low comorbidities

 American Society of Hematology

 64th ASH Annual Meeting and Exposition




Education Session: Beyond Routine Frontline Therapy of CML

Treatment of CML in Pregnancy. Jane Apperley, MB.

- Discussion on safety and management of planned or unplanned pregnancies during CML.
- Identification of the impact of TKI in fertility in men, and on pregnancy of partners of male CML patients.
- Revision of animal model studies on outcomes of pregnancy on TKI.
- Considerations when diagnosing CML during pregnancy, and pregnancy in established CML.
- With advances in clinical research and data revision, lately are physicians more likely to let patient get to term and less like to recommend termination.

Pregnancy outcomes & therapy by decade



Recommendations for women diagnosed with CML in pregnancy

- If possible, avoid any treatment
- Do not use hydroxycarbamide
- Leucapheresis will reduce high WCC
- Consider thromboprophylaxis
- Interferon (including pegylated) is safe
- Imatinib & ?nilotinib are safe in 3rd trimester

American Society of Hematology

64th ASH Annual Meeting and Exposition

Oral Abstract Sessions

621. Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Elisabetta Abruzzese, MD

Retrospective and prospective data obtained from 11 countries through the ELN CML pregnancy registry since 2001. Analysis of clinical and demographic data, therapy, pregnancy outcomes and follow-up were performed.

- There is a real possibility of normal childbirth in women diagnosed with chronic phase CML.
- Adjusting the treatment by pregnancy trimester, the risk for both the safety of the mother and infant can be balanced.
- IFN / PEG-IFN can be used from the first trimester.
- The use of HC has no advantages over Imatinib.

The outcomes for the children (n=66, one twin)

Gender:
boys 37 (56%) / girls 28 (42%) / no data 1 (2%)

Weight at birth (n=58):
median weight 3150 g (range 1700-4170 g).

Birth at term 58 (89%)
Preterm birth 7 (11%) - 34-36th week

Low birth weight (<2500 g): 7 (12%) children

Congenital abnormalities: 2 (3%)

- 1) abdominal skin angioma - exposed to IFN in 2-3 trimester and HC in 3rd trimester
- 2) patent foramen ovale - exposed to imatinib in 3rd trimester (week 33-35), born preterm

Follow-up of all children was reported as uneventful with normal development
Median follow-up 36 months (range 2 months – 17 years)

No	Therapy during pregnancy by trimester			outcome
	1 st trimester	2 nd trimester	3 rd trimester	
1	-	-	-	Birth at term
2	-	-	-	Birth at term
3	-	PEG-IFN	PEG-IFN	Birth at term
4	-	IFN	imatinib	Birth at term
5	-	imatinib	imatinib	Birth at term
6	-	imatinib	imatinib	Preterm birth
7	-	-	HC	Birth at term

Therapy during pregnancy

All patients n=86

- Miscarriage n=3
- Abortion n=18
- Pregnancy continuation n=65

No therapy during pregnancy n=23 (35%)

Therapy during pregnancy* n=42 (65%)

* the number does not reflect combination/switch of drugs

- Interferon**** n=28
 - Me start from 12th week (range 5-35 w)
 - 6 pts were switched to IM
 - Regular IFN** n=17
 - Doses: 3 MU daily (n=11), 6 MU daily (n=3), 9 MU daily (n=1)
 - 1 pt was transferred to PEG IFN (45 mcg)
 - PEG IFN** n=11
 - Weekly doses: 45 µg (n=2), 90 µg (n=1), 135 µg (n=6), 180 µg (n=3)
- Imatinib**** n=20
 - Me start from 18th week (range 16-34 w)
 - Daily doses: 400 mg (n=19), 400-600 mg (n=1)
- Hydroxycarbamide**** n=7
 - Daily doses: 2000 mg (n=3), 1500 mg (n=1), 1000 mg (n=2), dose unknown (n=2)

2 patients – for 3 and 5 days (1st and 3rd trimester)
5 patients - since 2-3rd trimester till labour
HC as monotherapy - 2 patients
HC in combination - 5 patients: HC+ IFN (n=2), HC + IM (n=3)

Leucapheresis in 5 patients : 2 patients without drug therapy, 2 patients on IFN and 1 patient on HC

**full label use at pregnancy, warranted if benefit outweighs risk


Oral Abstract Sessions

622. Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Andreas Burchert, MD

Results from ENDURE, CML-IX (NCT03117816), a multicenter, international phase III trial evaluating the role of a novel form of pegylated proline interferon-alpha 2b (ropeg-interferon-alpha, ropeg-IFN) in inducing TFR. Period between May 2017 and June 2021.

- RopegIFN does not improve the chance of achieving TFR in unselected TKI pre-treated patients.
- TKI exposure of 6 years or more and no prior stop attempt favors TFR induction by ropegIFN.
- RopegIFN is very well tolerated.





Oral Abstract Sessions

624. Racial and Ethnic Disparities in Survival Outcomes in Chronic Myeloid Leukemia

Catherine Sobieski, MD

The National Cancer Database was used to identify CML patients (pts) diagnosed from 2004-2019. Demographic and treatment characteristics were compared for White, Black, Asian, Hispanic and other minority populations. The OS was compared by race and ethnicity.

- Factors associated with improved survival include Asian and other races, Hispanic Ethnicity and Female gender.
- Limitations of the study due to underrepresentation of rural critical access hospitals, and lack of data on specific TKI therapy, adherence and side effects.
- Young black patients have worse OS than white patients
- Access to treatment remains a significant barrier.



Spotlight Sessions

Underrepresented minorities in clinical trials for hematologic malignancies: what's the data on the data?

Luciano Megala Costa, MD, PhD. University of Alabama at Birmingham Hospital / Sikander Ailawadhi. Mayo Clinic / Rayne Rouse, MD. Baylor College of Medicine, Texas Children's Hospital

Multiple myeloma represents an excellent scenario to study disparities in clinical trial participation and outcomes. It is a condition 2-3 times more incident in Black than in White individuals. Although individuals of racial-ethnic minorities are under-represented in clinical trials, when enrolled their outcome is the same or even better than in other patient groups.

- Proper clinical trial representation is required.
- No matter how well resourced a CT might be, there are costs to receiving care associated with participation, and they become a barrier.
- The eligibility criteria disproportionately can exclude the minority patients to participate in CTs.
- Lack of diversity in the workforce. Approaches to increase the proportion of underrepresented investigators in clinical research are required.

WHY sponsors/investigators don't accrue enough minority patients? – Eligibility criteria that disproportionately exclude minorities

Key Eligibility Criteria

- Male or female > 18 years of age at the time of screening
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Laboratory values meeting the following criteria within the screening period (or on the last day of study day):
 - Absolute Neutrophil Count (ANC) > 1,500/mm³ (or equivalent in SI units)
 - Platelet Count > 75,000/mm³ (or equivalent in SI units)
 - Hemoglobin > 8 g/dL (or equivalent in SI units)
 - Serum creatinine < 2.0 mg/dL (or equivalent in SI units)

• ANC in Whites ~ 700-2000 higher than in Blacks (Would you call it "Benign Ethnic Neutrophilia"?)

Merz LE et al. Blood Advances (Epub ahead of Print)

American Society of Hematology

CONSIDERATION FOR CLINICAL TRIAL ENROLLMENT

- Changing landscape in conduct of clinical trials
 - NCI/NCI-funded cooperative groups/academic centers
 - Involvement of patient advocacy groups
 - Pharmaceutical companies
 - Different mandates for representation in clinical trials (NIH vs FDA)
 - Slow but sure increase in awareness by patients
- Innovations in clinical trial designs:
 - Big randomized clinical trials vs. smaller, "smarter" trials
 - Some drugs receiving approvals on single-arm phase 2 trials
 - Smaller overall numbers of patients, homogeneity in patient population – *lesser diversity*


64th ASH Annual Meeting and Exposition

Spotlight Sessions

Underrepresented minorities in clinical trials for hematologic malignancies: what's the data on the data?

Potential strategies:

- Set concrete targets for trial enrolment
- Registration trials should specify how minority accrual will be optimized
- Having a trial diversity officer
- Provide culturally sensitive training to sites and staff
- Post-marketing specific data in minorities.



RACIAL COMPOSITION IN TRIALS SUPPORTING THE US APPROVAL OF ANTI-CANCER NEW MOLECULAR ENTITIES: 2011-2016

Overwhelming representation of white patients, more so in the United States

Race	Ex-US (N=17104)	US (N=6319)
White	78.7%	88.3%
African-American	0.7%	5.4%
Asian	16.6%	3.0%
Hispanic	0.1%	0.6%

Source: FDA-AACR Workshop to Examine Underrepresented Minority Participation in Clinical Trials

Diversity should be a forethought...a constant thought...**not an afterthought** in the quest to create clinical research opportunities for URiM.

Revisiting our cases...I invite us to have an open discussion about mitigation strategies based on **what we've discussed today.**

American Society of Hematology

64th ASH Annual Meeting and Exposition


Special-Interest Sessions

• Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session

Impact of Real-World Evidence on Research and Clinical Care: Priorities from ASH RC Data Hub

Adam Sperling, MD, PhD

- The ASH Research Collaborative aims to accelerate progress in hematology, foster collaborative partnerships and improve lives of people affected by blood diseases.
- Focused on capturing RWD in order to enhance care and accelerate research in hematology.



How the Data Are Used?

- Nested studies
- Decentralized studies
- Observational research
- Pandemic preparedness
- Local monitoring and QI
- National QI

Capturing Real-time RWD to Generate RWE

People Living with Hematologic Conditions → Data Hub → RESEARCH → ENHANCE CLINICAL CARE

Data Hub

- Real-World Data**
 - Electronic health records
 - Electronic case report forms/NLP for clinical information maintained outside structured EHR fields
 - Patient-reported outcomes
 - Patient-generated health data
 - Claims data
 - Other population data
- Multi-Stakeholder**
 - Patients and community members
 - Clinicians
 - Clinical care sites
 - Researchers
 - Quality improvement specialists
 - Federal entities

RESEARCH

- Contemporaneous Control Groups
- Post Market Surveillance
- Academic Research
- Cohort Identification

ENHANCE CLINICAL CARE

- Assess Site-Specific Outcomes
- Exchange Best Practices

64th ASH Annual Meeting and Exposition


Special-Interest Sessions

• Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session

HARMONY Alliance: Moving Toward Multicenter Real-World Data Capture in the Hematologic Malignancies in Europe - A Patient's Perspective.

Jan Geissler.

- After pre-clinical and clinical studies more effort should be made in collecting evidence of drug performance in the real world.
- Unwillingness to share data is the biggest risk to big data, as it is not in the patients' best interest, leads to delays in collective learning and duplication of research.
- The HARMONY Patient Cluster of 8 global patient umbrella organisations in hematology has contributed to central parts of the HARMONY project: data anonymisation, research proposals and core outcome sets.



Patient involvement in HARMONY:
De-facto anonymisation process, Delphi surveys and research proposals

HARMONY Alliance Patient Cluster

Logos: LeukaNET, Childhood Leukaemia International Groups, CML, ALAN, CLLAN, LYMPHOMA COALITION, MPO, MPN Association Patients

Contribution to de-facto anonymization procedure:

- Personal data
- Technical anonymization (Integration, organizational structure)
- Data access restrictions
- Organizational security policies, contracts
- De-facto anonymous data

Contribution to in Delphi surveys on Core Outcome Sets:

- Identify core outcome sets
- Delphi surveys
- Consensus building
- Final core outcome sets

Input into HARMONY research projects:

- Researcher involvement in project proposal
- Integration of results
- Submission of patient-led QoL/Tox research proposals

64th ASH Annual Meeting and Exposition

Big data is a huge opportunity to capture, analyse and act on real-world performance and patient reality of current treatments

- We're spending billions of \$€ on developing new treatments in pre-clinical research and clinical trials
- Afterwards, we are not putting much effort into evidence on their real world performance and whether they address patients' true needs
- EMA, FDA, WHO, patient community heavily pushing for more and better RWD and Patient Experience Data (e.g. FDA PFDD, EMA DARWIN)
- Big data: huge opportunity to capture and understand patient reality

Graph: Number of patients treated over time

- Legend:
 - Patients treated, no active surveillance
 - Patients in observational studies, registries, etc.
 - Patients in RCTs (or other interventional studies)
- Timeline: RCT, RWE, RWD, Analysis, RWE
- Annotations:
 - My "real" patients are here (pointing to RWD)
 - Safety (good number of responses in safety concerns)
 - Cost (high selective pathways)
 - Secondary endpoints (Good evidence)

FDA Patient Advocacy Session

During the meeting the FDA representatives gave an update on the relevant ongoing projects:

- Fostering Regulatory Science and Collaboration to Translate Real World Data into Real World Evidence.
- TEAM FoRWD - (**T**ranslational **E**valuation and **A**ssessment of **M**ethods to **F**acilitate use of **O**ncology **R**WD)
- Optimus - Get the dose right the first time
- FrontRunner - Advancing Development of New Oncology Therapies to the Early Clinical Setting
- Project Facilitate - Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products

For most of the meeting the importance of inclusion of PROs along the whole process of drug evaluations and development was addressed and discussed. As well as ways on how to get patients better involved in the drug development processes.

External sessions – ELN Breakfast

During the ELN Breakfast meeting held at ASH 2022 in New Orleans, reports from each WPs were presented, and an update session of the HARMONY Alliance was conducted. Within it, our Chair Jan Geissler presented a description of the research proposals submitted by the patient community to HARMONY.

- Prevalence of clinically relevant problems and symptoms in patients with CML
- A comparison study of "toxicity over time" and QoL among all available TKI options
- Correlation of demographic, disease and therapy factors with toxicity and tolerability of the different TKIs.

HARMONY **ALLIANCE** **CML** ADVOCATES NETWORK **ELN** Foundation European LeukemiaNet

CML QoL research proposals submitted to HARMONY by the CML patient community

ELN Breakfast Meeting

Jan Geissler and Eglys González
LeukaNET / CML Advocates Network

imi innovative medicines initiative efpia

BeiGene Patient Advocacy Event



“Cancer & Mental Health: The Science & Art of Whole Patient Care.”

Discussions on mental health during cancer diagnosis and therapy as part of quality cancer care. Presented from the view of psychologists and social workers. Aiming for a more personalized approach and support to the patients and their carers.

Allison Applebaum, PhD (Memorial Sloan Kettering Cancer Center)

Heather Honoré Goltz, PhD (University of Houston-Downtown)

Joseph A. Greer, PhD (Massachusetts General Hospital Cancer Center)


BeiGene has a program called **Talk About it: Cancer and Mental Health.**

- Mental health support can improve quality of life and health outcomes for individuals impacted by cancer.
- Aimed at patients and caregivers, healthcare professionals and policymakers.
- Designed to elevate the important intersection of mental health and cancer care.
- Talk About It will feature innovative empowerment strategies, advance public policy conversations, and inspire dynamic health equity initiatives to support people throughout their entire cancer journey.

Mental Health is a Critical Component of Quality Cancer Care

With support from BeiGene, a new Cancer Support Community survey of more than 600 U.S. cancer patients and survivors who faced emotional or mental health concerns revealed unmet needs and barriers to mental health care.

Emotional distress is prevalent across the cancer continuum, and the greatest number of people experience mental health concerns during **diagnosis, treatment, and recurrence**



Even those who are post-treatment or have no current evidence of disease often experience some form of emotional distress

iCMLf Forum: The next big challenges in CML?

- Free Treatment or Treatment Free? Where to invest limited resources in a highly manageable cancer

TKIs have not significantly affected the impact of a CML diagnosis on life expectancy, with outcomes remaining inferior in economically disadvantaged parts of the world. We need to ask how limited resources should be deployed for the greatest benefit.

- Disease Persistence in CML: Cell Intrinsic and Extrinsic Mechanisms

A lifetime of TKI therapy is associated with significant clinical and financial burden. While some individuals can discontinue therapy and remain disease free for years, low levels of disease persist in the majority of patients. Recent methodologic developments that enable to study of rare cell populations are providing an opportunity to understand this mechanism of this persistence, and identifying new targets.

- TKI Resistance: More Than Just Abl Mutations

Much attention has been paid to the development of kinase domain mutations as THE mechanism of resistance. However not all patients who develop resistance have detectable mutations. New data is emerging and old data re-emerging to understand resistance more broadly, and learn how to address it.

Panellist and patient advocate **Lisa Machado** expressed the patient community expectations on the ongoing research performed in CML and its therapies.

As well, the need of bringing clinical trials to underprivileged sites was brought up.



Poster Presentations

2303. Experiences and Views of Leukemia Patients: A Global Survey

Zack Pemberton-Whiteley, ALAN

- Acute leukemia patients appeared to be more worried about relapse than those with chronic leukemia
- Patients reported similar social wellbeing, social and physical behavior among acute and chronic leukemia, showing only few differences that can be explained by the nature of the disease, the urgency of treatment and available treatments in acute leukemia.
- 34% of patents with childbearing potential reported that fertility preservation was not discussed with their healthcare team.
- The data obtained supports that patient inclusion in decision-making and placing them at the center of care are still important needs. Efforts to achieve patient centricity are to be continued.

Experiences and Views of Leukemia Patients: A Global Survey

Zack Pemberton-Whiteley¹; Samantha Nier¹; Nick York²; Deborah Baker²; Michael Rynne²; Nicole Schroeter²; Denis Costello³; Lidija Pecova³; Esther Nathalie Oliva⁴; Tatyana Ionova⁴; Sam Salek⁴ and Jennie Bradley⁵

1- Acute Leukemia Advocates Network; 2- CLL Advocates Network; 3- CML Advocates Network; 4- HM-PRO; 5- IQVIA

Introduction
A deeper understanding of patients' experiences with leukemia is necessary given the ongoing discussions about patient-centricity and how to return the patient to the center of care.

The Acute Leukemia Advocates Network (ALAN) in collaboration with CLL Advocates Network (CLLAN) and CML Advocates Network (CMLAN) developed a multi-country survey to understand the issues and gather information on the current and emerging treatment landscape, experiences and quality of life (QoL) of adult patients with leukemia.

This survey was designed to focus on the patient perspective. This includes but not limited to: experiences through patient journey how it varies depending on the form of leukemia, the QoL and impact of leukemia on daily life, and what information and support was provided. Analysis of the data identified areas within the patient journey where opportunities exist to improve patient care and experiences.

Methods
Developed by a panel of leukemia patient advocates, the questionnaire was tested twice and comprises sixteen sections with the aim to collect insight and understanding into the patient's experience, rather than the clinical perspective. It did not seek to replicate the formal collection of scientific data such as patient preferences.

The questionnaire consists of 200 questions (some with sub-questions) including HM-PRO, a validated QoL assessment tool in those with hematological malignancies.

Patients completed the sections relevant to their type of leukemia. Data on relevant patient characteristics, such as gender, age, and countries of residence, were collected in the demographic section.

The administration of the questionnaire was web-based, between 18 September 2021 and 07 January 2022 and was made available in 10 languages. It was promoted by ALAN, CLLAN, CMLAN and member organizations via websites, newsletters, emails, and social media channels. Participation was on a voluntary basis therefore may not reflect the perspectives of all leukemia patients.

Results
There were 2646 respondents to the survey:

Leukemia Type	Respondents	%
Acute myeloid leukemia (AML)	312	12
Acute lymphoblastic leukemia (ALL)	104	4
Chronic lymphocytic leukemia (CLL)	1202	45
Chronic myeloid leukemia (CML)	896	34
Other types of leukemia	132	5
Total	2646	100

Of the 2646 patients who responded to the survey, 56% were female (n=1426), 56% were within the age range 55-74 years old (range <16 to >85), and living situation, employment status and education levels varied.

Responses were collected across 76 countries. Respondents were grouped into the designated World Health Organization regions; 66% (n = 1749) were from countries assigned to the European region, 14.7% (n=389) from the Americas region, 7.4% (n=195) from the Western-Pacific region, 2.1% (n=56) from Africa region and 1.5% (n=39) from Southeast Asia region.

Results
Overall, at diagnosis, 48% (n=1255, [49% ALL, 46% AML, 47% CLL, 49% CML]) of patients were offered written information on their leukemia without needing to ask for it. Of the 52% (n=1360, [57% ALL, 49% AML, 51% CLL, 53% CML]) who received written information, 57% (n=763 [61% ALL, 53% AML, 59% CLL, 55% CML]) of respondents partially / did not understand the information provided by their healthcare professional. In addition, 51% (n=1337, [32% ALL, 44% AML, 55% CLL, 51% CML]) were not offered or directed to any support to help with concerns and worries at diagnosis. The majority of patients who were not provided with written information or directed to support for concerns and worries reported they would have liked to receive these. Similar numbers are reported while under treatment.

Majority of acute leukemia and CML patients (93% ALL, 87% AML, 66% CML) started treatment within less than a week after diagnosis, while it took over 2 years for 41% of CLL respondents. Chemotherapy remains the standard treatment option for acute leukemias (48% ALL, 42% AML) while targeted therapy tablets are used for chronic leukemias (58% CLL, 79% CML).

62% (n=1271, [65% ALL, 59% AML, 52% CLL, 67% CML]) of respondents reported that they were not offered a choice of treatment options and half (n=1028, [55% ALL, 47% AML, 43% CLL, 55% CML]) were not involved as much in decisions about their treatment as they wanted to be. 60% (n=1225, [52% ALL, 41% AML, 54% CLL, 70% CML]) were not offered the option of participating in a clinical trial, and of these 43% (n=523, [32% ALL, 32% AML, 46% CLL, 44% CML]) reported they would have liked to have had this option.

Fatigue (n=1103, [57% ALL, 60% AML, 44% CLL, 55% CML]) is reported as the main side effects across all the leukemia types, but chronic leukemia patients (68% CLL, 65% CML) reported that their side effects were "barely noticeable" or had a "small impact" on their QoL, while acute leukemia patients (51% ALL, 44% AML) reported that their side effects had a large impact.

Acute leukemia patients also appeared to be more worried about relapse compared to chronic leukemia patients (more than 20% reported being "extremely worried").

Patients reported similar physical behavior, social wellbeing, and emotional behavior, however, more than 50% acute leukemia patients (57% ALL, 51% AML) reported feeling isolated (versus 35% CLL, 37% CML) and more than 70% had to stop working because of their acute leukemia (75% ALL, 78% AML versus 31% CLL, 37% CML) with a greater financial impact.

Of the patients with childbearing potential (age range considered 18-55 years), 34% (n=860, [19% ALL, 19% AML, 34% CLL, 40% CML]) reported that fertility preservation was not discussed with their healthcare teams.

Conclusion
We believe this survey is the largest ever conducted among leukemia patients to gather information about their experiences, QoL, and preferences.

Although the data reveals differing aspects of acute leukemia patients compared to chronic leukemia patients, to our surprise, in most areas investigated, they reported similar type of experiences. Where differences are observed, they can be explained by the nature of the disease, the urgency of treatment and the treatments currently available in acute leukemia.

Our data show that opportunities to provide patients with understandable information / emotional support are still being missed. Additionally, there is still a need to include patients in decision-making and to place them at the center of care (for example, to discuss treatment options and clinical trials, to preserve fertility, etc.), confirming the need to continue discussions on patient centricity.

2303 - 64th ASH Annual Meeting and Exposition - #ASH22

WWW.CMLADVOCATES.NET

Poster Presentations

1699. Chip-Based Digital PCR Platform, Lab on an Array, the Newly Developed Highly Accurate and Sensitive Method for the Detection of BCR-ABL1 Transcripts in Chronic Myeloid Leukemia

Hyun-Woo Song, PhD. Optolane Technologies

- To overcome some limitations of conventional qPCR and that of the dqPCR methods, the establishment of clinical guideline is crucial for wide application on TFR in CML. This group developed a novel technology, **a chip-based real-time dqPCR platform (LOAA; Lab On An Array; so called Dr. PCR™)** to achieve more stable, accurate and precise monitoring of BCR-ABL1 in a timely manner.
- Results showed that Dr PCR efficiently detects clinical specimens with low copy number of BCR-ABL1 compared to conventional qPCR.

Chip-based digital PCR platform including Lab On An Array, the newly developed highly accurate and sensitive method for the detection of BCR::ABL1 transcripts in Chronic Myeloid Leukemia

Hyun-Woo Song, PhD¹, Kyung-Mi Ki, MS², Soo Hyun Kim, MS², Sung-Hyun Kim, MD¹, Min-Sik Song, PhD¹, Seung-Shick Shin, PhD¹, and Dong-Wook Kim MD, PhD³

1. Bio Institute, Optolane Technologies Inc., Pangyo, Seong-Nam-Si, South Korea
2. Department of Hematology, Leukemia Omics Research Institute, Eulji Medical Center, Eulji University, South Korea
3. Department of Hematooncology, Dong-A University Medical Center, Dong-A University Royal Brisbane Hospital, Brisbane, Australia

1699

INTRODUCTION

With the development of various BCR-ABL1 tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) has become a manageable hematologic malignancy and current therapeutic goal is treatment free remission (TFR). To achieve a successful TFR in more patients, a precise assessment of minimal residual disease (MRD) has become one of the prerequisite requirements.

Since undetectable BCR-ABL1 fusion gene by conventional Taqman™-based quantitative polymerase chain reaction (qPCR) is not an indicator for complete eradication of CML clone, more precise methods should be developed.

Currently, to overcome some limitations of conventional qPCR, digital quantitative-PCR (dqPCR) methods have been developed for accurate and precise detection of various genes. However, current dqPCR methods may have limitations due to small dynamic range. Therefore, we have developed a novel technology, High Dynamic Range Digital Real-time PCR (HDR - Dr. PCR™) to achieve wider dynamic range, which allows more stable, accurate and precise monitoring of BCR-ABL1 in a timely manner.

METHOD

[Linearity Assessment]
RNA extracted from K562 (BCR-ABL1 e14a2 positive) was diluted with RNAs from HL60 (BCR-ABL1 negative).

[Equivalence Assessment]
Comparison of the efficacy of BCR-ABL1 detection between HDR - Dr. PCR™ and conventional qPCR was performed with clinical specimens obtained from leukemia patients.

[Conventional qPCR (2 Step RT-qPCR)]

- cDNA synthesis: Total 2 ug of RNA per test. Transcriptor First Strand cDNA Synthesis Kit (Roche, USA)
- qPCR: Real-Q BCR-ABL Quantification Kit (Bioscience, S. Korea)
- PCR equipment: Q55, Thermo Fisher, USA

[HDR - Dr. PCR™ (1 step RT-qPCR)]

- cDNA synthesis & dqPCR: 1 - 4 ug (for cell lines) or 4 - 10 ug (for clinical specimens) of RNA per test. HDR - Dr. PCR™ Kit (Optolane Technologies, S. Korea).
- dPCR equipment: LOAA (Optolane Technologies) with disposable Dr. PCR™ cartridges

RESULTS

Fig 1. Display of BCR-ABL1 transcript quantification using 1-step Digital Real-time PCR system (Dr. PCR™) by OPTOLANE

► The Digital Real-time PCR (called Dr. PCR™) is designed for simple workflow (approximately 1.5hr), which makes digital PCR a highly desirable for cancer diagnosis and minimum residual disease(MRD) monitoring.

► Due to the nature of real-time monitoring, Dr. PCR™ effectively distinguishes false positives which is one of the most concerns of end point droplet digital PCR instruments.

Cell line sample test

Fig 3. Linearity assessment using cell line RNA

► Linearity was assessed by the dilution of RNA of K562 with RNA of HL60 using 10-fold serial dilution of up to -7 log. The result showed accurate linearity (R² = 0.9972) at the range of BCR-ABL1/GUSB ratio of 10¹ to 10⁸ (%).

► Notably, HDR - Dr. PCR™ technology allowed to detect the level of BCR-ABL1 transcript of MR 6.34 (0.0000 %).

Clinical sample test

Fig 5. Correlation analysis of HDR - Dr. PCR™ vs RT-qPCR using clinical samples (a) linear regression (b) Bland-Altman plot

► Correlation analysis for 49 clinical samples with 0.0032 to 100 % showed that measured values from both qPCR and Dr. PCR were closely correlated with the R² of 0.982.

► LOA95 (limit of agreement at 95% confidence interval) analyzed by Bland-Altman plot was -0.515 ~ 0.246 (mean = -0.134), indicating the two methods are closely correlated.

Fig 2. Principle of High Dynamic Range Digital Real-time PCR. (a) C_t histogram for 7.8 x 10¹ to 7.8 x 10⁸ copies RNA samples. (b) Images of HDR - Dr. PCR™ 20k well and real-time amplification curves for 7.8 x 10¹ to 7.8 x 10⁸ copies RNA samples. (c) Dynamic ranges of RT-qPCR, digital PCR and HDR - Dr. PCR™.

► Since Dr. PCR™ utilizes real-time amplification curves of all the 20k wells, even highly concentrated samples of above dynamic ranges of conventional digital PCRs (over 10⁷ copies) can be calculated through the analysis of C_t distributions and average C_t value from the 20k curves.

► High Dynamic Range digital PCR (HDR - Dr. PCR™) allows advantages of not only digital PCR's high sensitivity and reproducibility but real-time PCR's wide dynamic range.

Fig 4. Linearity evaluation according to RNA input

► Figure 4 shows RNA inputs from 1 µg to 8 µg do not significantly change the reported MR values for the HDR - Dr. PCR™.

► When using Bug of RNA, HDR - Dr. PCR™ allowed the measurement of up to MR 6.34 with CV of 34.36%. Meanwhile, when using Log of RNA, it allowed up to MR 4.62 with CV of 20.47%.

Fig 6. Comparison test with clinical specimens of CML patients with BCR-ABL1 levels of lower than 0.0032%

► Total 10 clinical specimens of CML patients with BCR-ABL1 levels of lower than 0.0032% was measured using both qPCR kit and HDR - Dr. PCR™ kit. The result showed that HDR - Dr. PCR™ kit detected trace amount of BCR-ABL1 transcripts in additional 4 specimens compared to the detection by qPCR kit.

► All the 9 specimens detected by HDR - Dr. PCR™ kit were the specimens of lower than MR 5.0 which is out of the measurement range of the qPCR kit allows.

CONCLUSIONS

- High Dynamic Range Digital Real-time PCR (HDR - Dr. PCR™) allowed to measure BCR-ABL1 transcript level of MR 6.34 with 1-step RT-dqPCR reaction in one cartridge.
- The measurement and analysis are finished within 1.5 hr without the requirement of standard curve generation using standard materials.
- Comparing to conventional qRT-PCR technology, Optolane's novel digital real-time PCR (Dr. PCR™) with High Dynamic Range technology may minimize false positive results and maximize the analytical sensitivity of detecting BCR-ABL1 fusion transcripts and thus, would be useful for the accurate assessment of treatment in routine clinical practice and applying TFR.

REFERENCES

- Mojtahedi et al. *Nucleic acids research* 42.16 (2014): e126-e126.
- Goh, Hyun-Gyung, et al. *Leukemia & lymphoma* 52.5 (2011): 896-904.
- Mori, Silvia, et al. *American journal of hematology* 90.10 (2015): 910-914.
- Lee, Sung-Eun, et al. *Haematologica* 101.6 (2016): 717.
- Cross, N. C. P., et al. *Leukemia* 29.5 (2015): 999-1003.
- Spieß, Birgit, et al. *PLoS One* 14.3 (2019): e0214305.

ACKNOWLEDGEMENTS

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. NRF-2020M3A9B6038845).

CONTACT INFORMATION

Department of Hematology, Leukemia Omics Research Institute, Eulji Medical Center, Eulji University
E-mail: dwkim@eulji.ac.kr

OPTOLANE Technologies, Inc.
Phone: +82-31 737 7811
E-mail: info@optolane.com

Poster Presentations

1690. Minimally Invasive Blood Sampling for BCR::ABL1 transcript Monitoring

Vivian Oehler, MD. Fred Hutchinson Cancer Center

- For patients living in remote locations, monitoring can be financially burdensome. To address this need, this group developed a system to measure e13a2 and e14a2 BCR::ABL1 transcripts in capillary blood collected using the Tasso-M20 device.
- The assay was able to quantify accurately molecular responses associated with survival benefit (BCR::ABL1 transcripts $\leq 1\%$) and major molecular response (BCR::ABL1 transcripts $\leq 0.1\%$), but was less reliable at quantifying BCR::ABL1 transcripts $< 0.06\%$.
- This monitoring may improve CML molecular monitoring adherence by allowing at home patient-initiated sample collection.

Minimally Invasive Blood Sampling for BCR::ABL1 Transcript Monitoring

V.G. Oehler, MD^{1,2}, O. Sala-Torra, MD¹, Q.V. Wu¹, PhD, L. Beppu¹, E. Welch, PhD¹, E. Berthier, PhD¹, J.P. Radich, MD^{1,2}

1. Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, 2. Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, 3. Tasso, Inc., Seattle, WA, 4. Department of Medicine, Division of Oncology, University of Washington, Seattle, WA

INTRODUCTION

Chronic myeloid leukemia (CML) comprises ~15 to 20% of all adult leukemias. Most patients present in chronic phase (CP). With the availability of oral tyrosine kinase inhibitors (TKI) targeting BCR-ABL1, outcomes for CP CML patients have improved dramatically and the natural consequence of this greatly improved survival is that the number of CML patients alive and requiring continued treatment and disease monitoring is steadily increasing. This places an increasing burden on all facets of the health care system, including drug, laboratory, and health personnel costs.

For CML patients, adherence to treatment is critical and regular monitoring of treatment response is important, as specific treatment response milestones map to risk of disease progression. CML response is measured by quantifying BCR-ABL1 mRNA transcripts, the messenger RNA (mRNA) product of the translocation between chromosomes 9 and 22 that is the hallmark of CML. This is done by quantitative reverse-transcription polymerase chain reaction (RT-PCR). CML clinical trials have identified specific BCR-ABL1 transcript level treatment milestones associated with long-term survival, specifically BCR-ABL1 $\leq 1\%$ and $\leq 0.1\%$. Response also dictates when a change to an alternative TKI therapy, an intervention that can mitigate chronic adverse side effects and other long-term toxicities, improve quality of life, and limit costs to patients and health care systems.

A recent analysis of 1,188 newly diagnosed CML patients on Medicare in the US highlighted that only 32% had optimal monitoring defined as at least 3 tests in the first year. For patients living in remote locations, monitoring can be difficult and financially burdensome. In addition, the COVID-19 pandemic has highlighted that traveling for monitoring can be potentially unsafe, particularly for an individual with vulnerable health. The gap in testing is even more profound in low and middle-income countries (LMICs) where therapy is available, but routine testing is not.

RESULTS

Tasso-M20

- Dried blood collection
- Co-developed with a large pharma partner
- ~20 μ L of blood per tip x 4 tips (~80 μ L total)
- Volumetrically controlled dried blood
- High analyte stability

Figure 1. Tasso collection systems enable a broad and remote sampling capability

Patient ID	Age	Gender	Venous BCR-ABL1 (%)	Capillary BCR-ABL1 (%)
1	72	M	0.0047	Not detected
2	31	M	0.13	0.026
3	31	F	0.02	0.029
4	63	M	0.09	0.05
5	14	F	2.06	0.84
6	42	F	0.021	Not detected
7	76	F	0.36	0.02
8	37	F	0.067	Not detected
9	62	F	0.099	0.046
10	52	M	27.96	12.23
11	83	M	0.044	0.1
12	67	F	Not detected	Not detected
13	16	M	0.023	Not detected
14	44	F	0.014	Not detected
15	50	M	0.23	0.36
16	58	F	0.12	0.024
17	37	F	0.021	0.021
18	67	F	1	0.46
19	30	M	0.065	Not detected
20	28	M	1.45	0.52

Table 1. Patient characteristics, demographics, and % BCR-ABL1 transcript results

- Median age 51.5 years, range, 28-83 years
- Female gender, 55%
- Race/ethnic group:
 - American Indian or Alaska Native, 5%
 - Asian, 15%
 - Black or African American, 5%
 - White, 75% (5% Hispanic and Latino)

CONCLUSIONS

- The Tasso-M20 assay was able to quantify molecular responses associated with survival benefit (BCR::ABL1 transcripts $\leq 1\%$) and the procedure was well-tolerated.
- Less reliable at detecting and quantifying BCR::ABL1 transcripts $\leq 0.08\%$
- Capillary blood BCR::ABL1 transcript monitoring has the potential to improve CML molecular monitoring adherence by allowing at home patient-initiated sample collection.
- Globally, this approach could facilitate CML diagnostic testing for patients, a requirement to obtain therapy, and promote monitoring in geographic locations where conventional PCR testing is not feasible.
- With enhanced sensitivity, at home monitoring after TKI discontinuation may be feasible.

REFERENCES

- Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*. 2020;34(4):966-84.
- NCCN: clinical practice guidelines in oncology. Chronic Myeloid Leukemia V1.2023. National Cancer Comprehensive Network.
- Rowley S, Garcia-Gonzalez P, Radich JP, Nivolawski AG, Usherenko I, Balaguerina JB. Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries. *Cost Eff Resour Alloc*. 2021;19(1):18.
- Sala Torra O, Beppu L, Smith JL, Weidlen L, Georgievski J, Gupta K, et al. Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots. *Blood*. 2016;127(12):3773-4.
- Haack AJ, Lim FY, Kennedy DS, Day JH, Adams KN, Lee JJ, et al. homeNA: A Self-Sampling Kit for the Collection of Peripheral Blood and Stabilization of RNA. *Anal Chem*. 2021;93(9):3196-203.

ACKNOWLEDGEMENTS AND CONTACT INFORMATION

We would like to thank the patients who participated in this study.
Contact: voehler@fredhutch.org




Poster Presentations

1702. Chronic Myeloid Leukemia in Adolescents and Young Adults: Clinicopathological Variables and Outcomes

Mohammad Abdulla, MD. Hamad Medical Corporation

- Adolescents and young adults (AYAs) are defined as those between the ages of 15 through 39.
- This study aims to find out if AYA age group differ from older age group in clinicopathological variables or outcome.
- Results indicated that this group have a worse prognosis.
- Unique challenges for this population include fertility issues, access to health care, and survivorship concerns.
- Treatment free remissions are more important and more relevant for this age group.



INTRODUCTION

Chronic myeloid leukemia is most frequently diagnosed among people aged 65–74, with a median age of 65 (at diagnosis). [1] Adolescents and young adults (AYAs) have been defined as those diagnosed with cancer at ages 15 through 39. [2] In Qatar, we have a large number of patients that fall under the category of AYA, reflecting that most of the population is part of a relatively young workforce, with statistics confirming that the median age of the population of Qatar in 2021 was 32.5 years. [3] The classic Sokal score was derived from a pool of patients from 6 different studies with an age range of 5–84 years [4]. Other CML prognostic risk scores such as the Hasford, ELTOS, and ELTS scores have been derived using data from populations with median ages of 49, 52, and 51, respectively [5–7]. In all the populations studied for these scores, the percentages of patients considered to be AYA were limited.

AIM

We conducted this study to determine if AYA patients with CML differ from an older age group in clinicopathological variables or outcomes, which could indicate a unique disease pathology. We also compared risk scores to determine which score represents actual outcomes in AYA.

METHODS

We conducted a retrospective analysis of files of 224 patients who visited our center either as a new case or as a follow-up for CML between January 2012 and December 2020. Data were extracted on diagnosis, demographics, laboratory values, management, and outcomes. Patients were split into two groups according to age at diagnosis: < 40 years (AYA) or ≥ 40 years (older). The European Leukemia Net (ELN) 2013 recommendations were used for patient management and response evaluation [8].

CHRONIC MYELOID LEUKEMIA IN ADOLESCENTS AND YOUNG ADULTS: CLINICOPATHOLOGICAL VARIABLES AND OUTCOMES

M. A.J. Abdulla^{1,2}, M. B. Aldapt³, P. Chandrar⁴, S. El Akiki⁵, A. J. Nashwan⁶, L. J. Fernyhough^{1,7}, S. Sardar⁸, A. Chabra⁹, M. A. Yassin¹



1. Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar 2. Internal Medicine Department, Ibn Sina Specialized Hospital, Jenin, Palestine 3. Internal Medicine Department, Unity Hospital, Rochester Regional Health, New York 4. Medical Research Center, Biostatistics section, Hamad Medical Corporation, Doha, Qatar 5. Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar 6. Department of Nursing, Hazm Mebareek General Hospital, Hamad Medical Corporation, Doha, Qatar 7. Weill Cornell Medicine, Doha, Qatar 8. Department of Internal Medicine, Hamad General Hospital, Doha, Qatar

RESULTS

White blood cell count on diagnosis was significantly higher in the AYA group (187.5±148.8 vs. 136.1±103.2, p = 0.037), while hemoglobin level was significantly lower in the AYA group (10.5±2.21 vs. 11.40±2.01, p = 0.004). However, there was no significant difference in platelet count. Spleen size was bigger in AYA (19.8±5.2 vs 15.5±5.01, p = 0.001).

Despite these differences, patients in the AYA group were rated as having better prognoses overall based on the Sokal score, with more than half (55.8%) having a low-risk score, almost a third an intermediate risk score (31.2%), and only 13% a high-risk score. Conversely, patients in the older age group were rated as having worse prognoses based on Sokal scores, with only around a third in the low-risk group (32%), slightly less than half in the intermediate-risk group (44%), and a quarter in the high-risk category (24%). The same pattern was seen when using the Hasford score, but the ELTOS and ELTS scores showed a more comparable risk stratification between the two age groups.

When comparing the outcome at one year, 24 patients (35.8%) from the AYA group versus 10 (14.4%) from the older age group failed to achieve optimal response or had disease progression. The patients who achieved CCyR were comparable (AYA group = 21 (31.3%) vs. 20 (29.0%) in the older group). For MMR or deeper responses, 22 (32.9%) in the AYA group achieved this vs. 39 (56.3%) in the older group.

Kaplan Meier curve showed (A) Cumulative incidence of major molecular remissions (MMR); (B) Cumulative incidence of deep molecular remissions (DMR) across the two groups

Parameters	Age at diagnosis < 40 years Mean±SD [median (range)] n=114	Age at diagnosis ≥ 40 years Mean±SD [median (range)] n=110	P-value
Gender			0.994
Male	84 (73.7%)	81 (73.6%)	
Female	30 (26.3%)	29 (26.4%)	
WBC at diagnosis	187.5±148.8 [142.3 (5, 612)]	136.1±103.2 [120 (3.3, 521)]	0.037
Blasts (%) at diagnosis	3.58±5.40 [2 (0, 38)]	2.79±7.4.09 [2 (0, 34)]	0.130
Hemoglobin at diagnosis	10.5±2.21 [10.5 (6.1, 15.5)]	11.40±2.01 [11.4 (6.5, 16.4)]	0.004
Platelet at diagnosis	360.1±216.5 [318 (48, 1294)]	394.7±308.2 [321 (18, 2158)]	0.758
Spleen size at diagnosis (in cm)	19.8±5.2 [19 (8.1, 29.2)]	15.5±5.01 [14.1 (6.6, 27)]	0.001
Disease phase on diagnosis			
CP	92 (83.6%)	93 (88.6%)	
AP	12 (10.5%)	10 (9.5%)	
BP-ALL	2 (1.8%)	2 (1.9%)	
BP-AML	4 (3.6%)	0 (0%)	0.254
Outcome at 1 year by MR			0.111
Progression / Failure	24 (35.8%)	10 (14.4%)	
CCyR	21 (31.3%)	20 (29.0%)	
MMR	22 (32.9%)	39 (56.3%)	
DMR	12 (18.0%)	18 (25.9%)	
Final outcome			
MMR	55 (56.7%)	69 (73.4%)	0.016
DMR	36 (37.7%)	44 (46.8%)	0.175
Death	3 (2.6%)	1 (0.9%)	0.330

CONCLUSION

AYA presents a unique age group. This study indicates a worse prognosis despite their younger age, despite most major risk scoring systems including older age as a worse prognostic factor. More studies are warranted to clarify the differences in CML disease biology and its possible effect on the outcome and formulate a new risk score for this age group.

REFERENCES

- https://www.cancer.gov/statfacts/html/cmll.html
- Adolescent and Young Adult Oncology Progress Review Group. "Closing the gap: research and care imperatives for adolescents and young adults with cancer." NIH Publication No. 06-0067 (2006).
- https://www.population.gov.qa/en/
- Sokal, Joseph E. et al. "Prognostic discrimination in 'good-risk' chronic granulocytic leukemia." (1984): 780-795.
- Hasford, Joerg, et al. "A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group." NCI Journal of the National Cancer Institute 95: 11 (1998): 850-859.
- Hasford, Joerg, et al. "Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the ELTOS score." Blood, The Journal of the American Society of Hematology 118: 3 (2011): 686-692.
- Pflemmer, Markus, et al. "Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia." Leukemia 30: 1 (2016): 49-56.
- Baccarani, Michele, et al. "European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013." Blood, The Journal of the American Society of Hematology 122: 6 (2013): 872-884.

REFERENCES CONT.

CONTACT INFORMATION

Mahmood B. Aldapt: mahmoodaldapt@gmail.com
 Mohammad A.J. Abdulla: dr.majabdulla@gmail.com
 Mohamed A. Yassin: Yassinmoha@gmail.com

Poster Presentations

1708. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas. Hospital Ramón y Cajal

- This is a retrospective study of 77 CML patients from 36 centers, who have failed the second-generation TKI. All of them received Asciminib through a compassionate program.
- A dose adjustment was required, being more frequent in the intolerant group than in the group resistant to previous lines.
- 73% of patients maintained or achieved a complete cytogenetic response (CCyR) and 60% a major molecular response (MMR).
- Responses were much better in patients who started asciminib for intolerance than in those who started it for resistance

TOXICITY OF ASCIMINIB IN REAL CLINICAL PRACTICE; ANALYSIS OF SIDE EFFECTS AND CROSS-INTOLERANCE WITH TYROSINE KINASE INHIBITORS

L. Pérez-Lamas¹, A. Luna¹, C. Boscá², M.A. Serini², B. Xicoy¹, P. Gralado¹, R. Pérez López³, C. Ruiz Nariño⁴, N. De las Heras⁵, E. Mora Castañer⁶, C. García-Hernández⁷, A. Segura Díaz⁸, J.L. Steegmann⁹, P. Velez Tenza¹⁰, F. Sanchez-Guipó¹¹, AM. García-Nobajas¹², JA. Vara Gohí¹³, M. Moreno Vega¹⁴, A. Alvarez-Laman¹⁵, M. Cortes¹⁶, M. Pérez Encinas¹⁷, L. Serrano¹⁸, A. Angona¹⁹, A. Rosell²⁰, S. Lakhwani²¹, M. Colorado²², E. Ramila²³, C. Cervero²⁴, B. Cuevas²⁵, L. Villalón Blanco²⁶, JC. Hernández Bolaños²⁷, A. Paz Colás²⁸, V. Gómez²⁹, MJ. Fernández³⁰, L. Falga Casado³¹, JM. Alonso-Dominguez³², MM. Anguita Arance³³, P. Carrasco Mastel³⁴, A. Salamanca Cuenca³⁵, A. Jiménez-Velasco³⁶, MJ. Ramirez³⁷, M. López-Caballero³⁸, M. Sierra Pacheco³⁹, M. Santalucia⁴⁰, O. Alba Alvarez⁴¹, R. De Paeck⁴², V. Garcia-Gutierrez⁴³

INTRODUCTION

Although Tyrosine Kinase Inhibitors (TKIs) have changed the natural history of chronic myeloid leukemia (CML), still a significant percentage of patients fail the TKIs available to date, many due to intolerance. Asciminib is a first-in-class BCR-ABL1 inhibitor specifically targeting the myristoyl pocket of ABL1. Since adverse events (AEs) are mostly related to inhibition of non-target kinases by ATP-binding TKIs, asciminib could provide improved tolerability. Asciminib has demonstrated a good safety profile in clinical trials¹ and in some preliminary studies in real clinical practice recently reported by several groups².

RESULTS

Data from 77 patients were analyzed, their baseline characteristics are shown in Table 1.

Characteristic	Patients (n=77)
Median age at diagnosis (range)	62 (45-82)
Median age at asciminib (range)	52 (22-83)
Female (%)	28 (36.4)
Median time to progression (TKI), years (range)	1.2 (0.2-8.6)
Median time from asciminib to progression (TKI), years (range)	1.2 (0.1-8.5)
Median time from asciminib to relapse (TKI), years (range)	1.2 (0.1-8.5)
Median time from asciminib to death (TKI), years (range)	1.2 (0.1-8.5)
Median time from asciminib to last assessment (TKI), years (range)	1.2 (0.1-8.5)

55% of patients had some AE with asciminib, most of them mild (grades 1-2), with 18% being grade 3-4.

None of the patients with previous cardiovascular events presented a new event. One patient experienced a worsening of his pre-existing peripheral arterial disease (PAD), but there were no de novo cases.

In 20 patients a dose adjustment was required and in 19 of them a temporary suspension of treatment. The need for dose adjustment was more frequent in the intolerant group than in the group resistant to previous lines (33% vs 14%). Patients who required a dose reduction had an MMR rate at the end of follow-up of 55% (11/20) vs. 53% (34/54) in those who maintained standard doses. 8% (8/77) of patients had to stop treatment definitively due to side effects (pleural effusion, pneumonitis, renal failure, worsening of PAD, two due to pancreatitis).

When comparing AEs of asciminib versus previous classical TKIs, a lower percentage of cytopenias was observed (Figure 2).

AIM

- Perform an analysis focused on the toxicities shown with asciminib.
- Study cross-intolerances with other TKIs, which may limit the expected success.

METHOD

An observational, multicenter, retrospective study has been carried out with data from 77 patients with CML from 36 centers, who had presented a therapeutic failure to second-generation TKI, due to intolerance or resistance. All of them received asciminib through a compassionate use program between October 2018 and June 2022.

CONCLUSIONS

- Asciminib is a molecule with a good safety profile, with a lower rate of AEs compared to classical TKIs.
- However, this drug, despite its novel mechanism of action presents risk of cross-intolerance with classical TKIs for some toxicities, including hematologic toxicity, fatigue, vomiting and pancreatitis.

REFERENCES

1. Delphine Réa et al. A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. Blood. 2021.
2. Valentín García-Gutiérrez et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 2021.

CONTACT INFORMATION

Email: luciaperezlamas@hotmail.com

Hospital Universitario Ramón y Cajal

Logo: GE, EIMC, ir-cis

Figure 1. Adverse effects with asciminib divided by severity (3%).

Adverse Effect	Grade 1-2 (%)	Grade 3-4 (%)
Fatigue	28%	2%
Thrombocytopenia	28%	2%
Anemia	28%	2%
Arthralgia	28%	2%
Nausea on working	28%	2%
Headache	28%	2%
Dizziness	28%	2%
Diarrhea	28%	2%
Upper respiratory tract infection	28%	2%
Cough	28%	2%
Stomach pain	28%	2%
Constipation	28%	2%
Weight loss	28%	2%
Hypertension	28%	2%
Heart rate peripheral	28%	2%
Skin rash	28%	2%
Liver enzyme increase	28%	2%
Diabetes	28%	2%

Figure 2. Frequency of hematologic toxicity with previous TKI versus asciminib.

Toxicity	TKI (n)	TKI (%)	Asciminib (%)
Neutropenia	TKI1	25%	10%
	TKI2	30%	12%
	TKI3	20%	8%
	TKI4	15%	6%
	TKI5	10%	4%
	TKI6	5%	2%
Anemia	TKI1	20%	8%
	TKI2	25%	10%
	TKI3	15%	6%
	TKI4	10%	4%
	TKI5	5%	2%
	TKI6	2%	1%
Thrombocytopenia	TKI1	15%	6%
	TKI2	20%	8%
	TKI3	10%	4%
	TKI4	5%	2%
	TKI5	2%	1%
	TKI6	1%	0%

Figure 3. Frequency of extra-hematologic toxicity with previous TKI versus asciminib.

Toxicity	TKI (%)	Asciminib (%)
Headache	25%	10%
Pleural/pericardial effusion	15%	5%
Diarrhea	10%	3%
Skin ulcers	5%	1%

Table 1. Baseline characteristics of the cohort.

Characteristic	Patients (n=77)
Median age at diagnosis (range)	62 (45-82)
Female (%)	28 (36.4)
Median time to progression (TKI), years (range)	1.2 (0.2-8.6)
Median time from asciminib to progression (TKI), years (range)	1.2 (0.1-8.5)
Median time from asciminib to relapse (TKI), years (range)	1.2 (0.1-8.5)
Median time from asciminib to death (TKI), years (range)	1.2 (0.1-8.5)
Median time from asciminib to last assessment (TKI), years (range)	1.2 (0.1-8.5)

Table 2. Frequency of the different toxicities with each of the lines of treatment and with asciminib. In orange, cross-intolerance. Frequency in the group with a history of the adverse effect and frequency in the group without a history of the adverse effect.

Toxicity	Group	Frequency (%)
Neutropenia	TKI	20%
	Asciminib	10%
	Cross-intolerance	5%
	Without cross-intolerance	15%
Anemia	TKI	15%
	Asciminib	8%
	Cross-intolerance	3%
	Without cross-intolerance	12%
Thrombocytopenia	TKI	10%
	Asciminib	6%
	Cross-intolerance	2%
	Without cross-intolerance	8%

With a median follow-up of 13.7 months, 71% of the patients continued treatment with asciminib. Of the total dropouts, 722 were due to intolerance, 10/22 due to resistance and 5/22 due to death from any cause (pharyngeal neoplasm, hepatic adenocarcinoma, skin ulcer with calyphylaxia, two unknown cause).




Poster Presentations

2306. Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Fabio Efficace, PhD. GIMEMA



- This study examined QoL and the impact of financial burden in QoL of patients from the only Ethiopian center providing TKI therapy to CML patients from all over the country. Tikur Anbessa Hospital
- The top three most prevalent clinically relevant problems were physical functioning (60%), emotional functioning (40%) and social functioning (38%), being pain the most prevalent symptom. Contrary to what is seen in high-income countries, financial difficulties was the most reported (89%) non-clinically relevant problem.
- It was observed a statistical significant association of higher financial difficulty with a greater impact on daily life.



HEALTH-RELATED QUALITY OF LIFE AND FINANCIAL BURDEN OF ETHIOPIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS

FISHATSION TADESSE¹, AMHA GEBREMEDHIN¹, ABDULAZIZ ABUBEKER¹, ALFONSO PICIOCCHI², MARTA CIPRIANI², LALISE GEMECHU¹, ATALAY MULU¹, GETAHUN ASRES³, FABIO EFFICACE²

¹Department of Internal Medicine, College of Health Sciences, Addis Ababa University; ²Italian Group for Adult Hematologic Diseases (GIMEMA), Health Outcomes Research Unit, Rome, Italy; ³Department of Internal Medicine, College of Medicine and Health Sciences, University of Gondar

INTRODUCTION

Assessment of health-related quality of life (HRQoL) of patients with chronic myeloid leukemia (CML) treated with modern tyrosine kinase inhibitors (TKIs) is critical to support informed decision-making. However, HRQoL data currently available mainly stems from patients enrolled in high-income high-income countries. Little is known about HRQoL of patients with CML living in low-income African countries and on the potential impact of financial constraints experienced by these patients.

METHODS


This was an observational cross-sectional study conducted at Tikur Anbessa Hospital (Addis Ababa), which is the only Ethiopian center providing TKI therapy to CML patients from all over the country. Adult patients (at least 18 years old) with a confirmed diagnosis of CML were eligible for this study. At study entry, HRQoL was assessed with the EORTC QLQ-C30 and the QLQ-CML 24 questionnaires. Prevalence of clinically important problems and symptoms, at the patient level, was examined using established criteria for the use of the EORTC QLQ-C30 in routine clinical practice. This prevalence reflects the number of patients indicating limitations of everyday life, worrying, or need for help or care related to a specific symptom or functional impairment [1]. For descriptive purposes, EORTC QLQ-CML 24 scores of Ethiopian patients were compared to that of patients included in the validation study of this questionnaire, which were nearly all enrolled from high-income countries [2]. Multivariable linear regression analysis was performed to examine the association between financial difficulty on "impact on daily life" (EORTC QLQ-CML24) while controlling for key potential observed confounding factors. The study was approved from ethical committee of the institution and all patients provided informed consent.

AIM

The main objective of this study was to examine prevalence of clinically relevant problems and symptoms of Ethiopian patients with CML. A secondary objective was to investigate the impact of financial burden on HRQoL profile of these patients.

RESULTS

Between February 2021 and June 2021, 395 patients were consecutively enrolled. Median age of patients was 39 years (range 18-82) and there were 62.8%, and 37.2% of males and females' patients respectively. Median time since diagnosis was 3.9 years (range 0.2-16) and 94% were diagnosed in chronic phase (CP) of the disease. The majority of patients (92.7%) were in treatment with imatinib and, overall, 82.3% were in complete hematologic response but unknown molecular remission status. The majority of patients (82.8%) were not able to afford follow-up BCR-ABL tests to monitor molecular response. **The top three most prevalent clinically important problems were found for physical functioning (60%), emotional functioning (40%) and social functioning (38%). Pain was the most prevalent clinically important symptom reported by 43% of patients. Notably, 89% of patients reported relevant financial difficulties.** Mean EORTC QLQ-C30 global health status/QoL score of patients with higher financial difficulties was 14 points lower (worse) than those with lower financial difficulties (P<0.001) (Figure 1). Gender specific descriptive comparison of Ethiopian patients with CML patients mainly from high-income countries, revealed worse mean scores in key domains of the EORTC QLQ-CML24. For example, male Ethiopian patients reported a higher (worse) mean score (+25.2 points) than male patients from high-income countries (Table 1). In the multivariable analysis, higher financial difficulty, was associated (P<0.001) with a greater impact on daily life (EORTC QLQ-CML24) and this was independent of other key variables including: age, sex, time since diagnosis, comorbidity, distance to hospital as well as fatigue and symptom burden.



	Male patients from the QLQ-CML 24 validation study (N=426)	Male Ethiopian Patients (N=248)	Female patients from the QLQ-CML 24 validation study (N=350)	Female Ethiopian Patients (N=147)
EORTC QLQ-CML 24 scales	M (SD)	M (SD)	M (SD)	M (SD)
Symptom burden (SB)	19.6 (15.0)	21.1 (17.6)	23.8 (15.8)	23.8 (18.1)
Impact on worry/mood (WA)	19.8 (17.5)	29.9 (24.8)	23.7 (19.8)	31.0 (24.7)
Impact on daily life (DL)	25.3 (20.7)	45.5 (30.0)	23.5 (22.1)	44.4 (27.0)
Body image problems (BI)	16.3 (25.4)	21.9 (33.0)	21.8 (29.1)	22.9 (34.0)
Satisfaction with care and information (SA)	85.8 (22.6)	86.6 (20.8)	77.9 (25.3)	89.5 (27.0)
Satisfaction with social life (SS)	69.4 (27.1)	68.0 (30.7)	64.8 (29.0)	62.6 (34.0)

Abbreviations: M=mean; SD=standard deviation; HRQoL=Health-related quality of life.
Legend: A higher score in SB, WA, DL and BI reflects a larger impairment in the corresponding domain, while a higher score on the SA and SS scales reflects a higher level of satisfaction.

CONCLUSIONS

Financial burden is a major problem affecting a large proportion of Ethiopian patients with CML receiving TKIs. Our findings also suggest that financial difficulties of these patients are also associated with worse HRQoL outcomes. Future studies are needed to assess whether efforts to reduce financial burden in these patients could improve HRQoL and facilitate adherence to therapy, thereby maximizing TKIs efficacy.

REFERENCES

- Giesinger JM et al. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. *J Clin Epidemiol.* 2020;118:1-8
- Efficace F et al. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. *Leuk Lymphoma.* 2021;62:669-678.

CONTACT INFORMATION

Prof. Fabio Efficace
Head, Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), GIMEMA Data Center
Phone: +39 06441639831
E-mail: f.efficace@gimema.it

WWW.CMLADVOCATES.NET

ASH 2022

